GIP (Active) ELISA - Cosmo Bio Co.,Ltd.

Antibodies

>

GIP (Active) ELISA

Catalog No.: YII-YK252-EX
Size: 1KIT
Price: ¥79000
$1054
antigen/source: GIP (Active)
Storage: 4C
@
Immunogen: Mouse
Measurement Range: 7.8 - 500 pg / mL
Purpose: Determination of Mouse GIP(Active) in plasma sample
component: Antibody: X
Plate: X
Coating: X
Control: -
Standard: X
Labeling: X
Substrate: X
Others: X
1. Antibody coated plate
2. Standard
3. HRP labeled antibody solution
4. Enzyme substrate solution (TMB)
5. Stopping solution
6. Buffer solution
7. Washing solution (Concentrated)
8. Adhesive foil

Other:

 Supplementary 
Sandwich
 Applicable sample 
mouse plasma (EDTA-2Na + DPP-4 inhibitor) and culture medium supernatant
[Other]
 Background 
The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagons-like peptide-1 (GLP-1), are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after ingestion of food.
This ELISA kit has high specificity to mouse GIP (1-42) active form and shows no crossreactivity to mouse GIP (3-42) inactive form.
 Assay range 
7.8 - 500 pg/mL
 Specificity 
This ELISA kit has high specificity to human GH(1-43) and shows no crossreactivity tohuman GH(1-191).
[Kit Characteristics]
The assay is completed within 2 hr + 1 hr + 0.5 hr
With one assay kit, 40 samples can be measured in duplicate
Test sample: mouse plasma(EDTA-2Na + DPP-4 inhibitor) 25 uL
The kit can be used dividedly in strips.
Intra-assay CV(%): 5.8-6.0
Inter-assay CV(%): 1.6-3.3


Reference:

•  Brown J.C. et al., J.Physiol. 209 57-64 (1970)
•  Jornvall H et al., FEBS Lett. 123 205-210 (1981)
•  Moody A.J. et al., Diabetologia 21 306 abstr (1981)
•  Carlquist M et al., Eur.J. Biochem. 145 573-577(1984)
•  Moody, A.J. et al., FEBS Lett. 172 142-148 (1984)
•  Takeda J. et al., Proc Natl Acad Sci USA 84 7005-7008 (1987)
•  Pederson R.A. et al., Gut Peptides: Biochemistry and Physiology, eds, Walsh, J.H.& Dockray, G.J. (Raven, New York), pp,217-260 (1994)
•  Rabinovitch A. et al., Endocrinology 94 1139-1144 (1974)
•  Dupre J. et al., J. Clin. Endocrinol. Metab. 37 826-828 (1973)
•  Elahi D. et al., Am.J.Physiol. 237 E185-E191 (1979)•  Krarup T et al., J Clin Endocrinol Metab. 56 1306-1312 (1983)
•  Naitoh R et al., Biochem Biophys Res Commun. 376 21-25 (2008)
•  Miyawaki K et al., Proc Natl Acad Sci USA 96 14843-14847 (1999)
•  Miyawaki Ket al., Nat Med. 8 738-742 12 (2002)
•  Tsukiyama K et al., Mol Endocrinol 20 1644-1651 (2006)
 
>